Short answer
Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Cullinan announced anticipated fourth-quarter 2026 development milestones.
Cullinan Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Cullinan announced anticipated fourth-quarter 2026 development milestones
- Milestone timing may influence investor expectations for upcoming clinical and regulatory catalysts
- Full milestone details are in Exhibit 99.1 accompanying the 8-K
Item 8.01 · Other Events
- Fourth-quarter 2026 catalysts span CLN-978 immunology data across SLE, RA and Sjögren’s disease
- December CLN-978 readouts include multi-dose and single-target regimens from three ongoing Phase 1 trials
- Velinotamig Phase 1 SLE multi-dose data expected at ACR Convergence 2026 in November
- December CLN-049 Phase 1 dose-escalation update targets relapsed/refractory acute myeloid leukemia
Item EX-99.1 · Exhibit EX-99.1
- Q4 2026 catalyst slate centered on clinical updates across autoimmune disease and oncology T-cell engager programs
- CLN-978 multi-dose and single-dose data in SLE, RA, and Sjögren’s disease expected in December
- Velinotamig SLE multi-dose data scheduled for ACR Convergence 2026 on November 8
- CLN-049 Phase 1 AML dose-escalation update expected in December, supporting potential Phase 2 advancement
- Data timing creates near-term valuation catalysts, with clinical efficacy and safety outcomes remaining key risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cullinan Therapeutics, Inc. 8-K filings
Get the next CGEM 8-K as it lands
Follow CGEM for push alerts, or ask the research agent what this filing means.